Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Generic Name
- Recombinant Human Granulocyte/Macrophage Colonystimulating Factor（rhGM-CSF）
- Indication
用于：1.恶性肿瘤、白血病化、放疗引起的白血病减少及其并发的感染；
2.造血干/祖细胞移植后髓系造血功能受抑及延迟植活与移植排斥；
3.与rhG-CSF等造血生长因子联合或单独应用于外周血造血干/祖细胞移植前的干/祖细胞动员；
4.再生障碍性贫血等骨髓衰竭性疾患及各种严重感染并发的中性粒细胞减少；
5.也可用于艾滋病本身、或因药物治疗所致的中性粒细胞减少。
Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2007-03-21
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 9
- Registration Number
- NCT00450008
- Locations
- 🇺🇸
The Methodist Hospital Research Institute, Houston, Texas, United States
Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer
- First Posted Date
- 2007-03-16
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00448409
- Locations
- 🇺🇸
The Methodist Hospital Research Institute, Houston, Texas, United States
Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 31
- Registration Number
- NCT00447473
- Locations
- 🇺🇸
Baylor College of Medicine - Methodist Hospital, Houston, Texas, United States
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00446173
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Herceptin and GM-CSF for Metastatic Breast Cancer
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT00429104
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2006-12-25
- Last Posted Date
- 2018-08-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00415857
- Locations
- 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States
Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation
- Conditions
- LymphomaLeukemiaTransplantation, Stem CellLymphoid MalignanciesDisorder Related to Transplantation
- Interventions
- First Posted Date
- 2006-10-04
- Last Posted Date
- 2019-07-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00383994
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Cellular Immune Augmentation in Colon and Rectal Cancer
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 20
- Registration Number
- NCT00257322
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- Rita Sanghvi, Mehta
- Target Recruit Count
- 48
- Registration Number
- NCT00256243
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
Neoadjuvant Treatment of Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-11-16
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 43
- Registration Number
- NCT00254592
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.